Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 2/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288968 | 0.92 | MAPT (0.47) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6292820 | 0.90 | MAPT (0.57) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6289686 | 0.89 | MAPT (0.46) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6288926 | 0.89 | MAPT (0.46) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6293072 | 0.87 | MAPT (0.44) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6289777 | 0.86 | MAPT (0.44) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6289308 | 0.86 | MAPT (0.59) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6288945 | 0.78 | LMNA (0.38) | MAPTEDNRBEDNRAPIK3CD | |
| SCHEMBL6289631 | 0.77 | EDNRA (0.41) | MAPTALDH1A1MEN1PKMKMT2A | |
| SCHEMBL6289621 | 0.76 | EDNRA (0.48) | ALDH1A1EDNRBEDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | MAPT 4430/4885ALDH1A1 1527/4885MEN1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.